# Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat

> **NCT00791011** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 33 (actual)

## Conditions studied

- Hodgkin's Lymphoma
- Low Grade Lymphoma
- Lymphoma
- Mantle Cell Lymphoma
- Non-Hodgkin's Lymphoma
- Diffuse Large Cell Lymphoma

## Interventions

- **DRUG:** AMG 655
- **OTHER:** Vorinostat
- **OTHER:** Bortezomib

## Key facts

- **NCT ID:** NCT00791011
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2010-07
- **Final completion:** 2011-08
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2014-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00791011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00791011, "Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00791011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*